

SUPPLEMENTAL TABLE 2. Rates of cardiovascular morbidity and mortality in the genetic subsample of Look AHEAD.

		All participants		Participants without a history of CVD at baseline	
		DSE	ILI	DSE	ILI
Primary Outcome	All participants	339 / 16,991 (2.00)	333 / 17,829 (1.87)	225 / 15,041 (1.50)	201 / 15,708 (1.28)
	Non-Hispanic White	265 / 11,940 (2.22)	244 / 12,184 (2.00)	172 / 10,439 (1.65)	137 / 10,643 (1.29)
	African-Americans	39 / 2,766 (1.41)	57 / 2,876 (1.98)	28 / 2,539 (1.10)	44 / 2,580 (1.71)
	Hispanic / NA	35 / 2,285 (1.53)	32 / 2,769 (1.16)	25 / 2,063 (1.21)	20 / 2,485 (0.80)
Secondary Outcome 1	All participants	229 / 17,612 (1.30)	218 / 18,422 (1.18)	150 / 15,438 (0.97)	127 / 16,059 (0.79)
	Non-Hispanic White	176 / 12,455 (1.41)	154 / 12,621 (1.22)	111 / 10,766 (1.03)	83 / 10,864 (0.76)
	African-Americans	28 / 2,823 (0.99)	42 / 2,968 (1.41)	21 / 2,579 (0.81)	31 / 2,663 (1.16)
	Hispanic / NA	25 / 2,334 (1.07)	22 / 2,832 (0.78)	18 / 2,092 (0.86)	13 / 2,532 (0.51)
Secondary Outcome 2	All participants	420 / 16,992 (2.47)	405 / 17,830 (2.27)	291 / 15,042 (1.93)	257 / 15,708 (1.64)
	Non-Hispanic White	326 / 11,941 (2.73)	299 / 12,185 (2.45)	222 / 10,440 (2.13)	181 / 10,643 (1.70)
	African-Americans	50 / 2,766 (1.81)	65 / 2,876 (2.26)	36 / 2,539 (1.42)	51 / 2,580 (1.98)
	Hispanic / NA	44 / 2,285 (1.93)	41 / 2,769 (1.48)	33 / 2,063 (1.60)	25 / 2,485 (1.01)
Secondary Outcome 3	All participants	479 / 16,598 (2.89)	476 / 17,440 (2.73)	327 / 14,838 (2.20)	309 / 15,439 (2.00)
	Non-Hispanic White	364 / 11,672 (3.12)	353 / 11,874 (2.97)	240 / 10,331 (2.32)	222 / 10,419 (2.13)
	African-Americans	62 / 2,698 (2.30)	75 / 2,842 (2.64)	48 / 2,477 (1.94)	58 / 2,558 (2.27)
	Hispanic / NA	53 / 2,228 (2.38)	48 / 2,724 (1.76)	39 / 2,030 (1.92)	29 / 2,462 (1.18)

Numbers denote total number of events, total person-years of follow-up, and rate of event per 100 person years. NA denotes Native-American.

Primary composite outcome includes death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina. Secondary Outcome 1 includes death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary Outcome 2 includes death from any cause, nonfatal myocardial infarction, or nonfatal stroke. Secondary Outcome 3 includes death from any cause, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, CABG, PCI, hospitalization for heart failure, carotid endarterectomy, or peripheral vascular disease.